Biotech News
Related news
CRBUCaribou2026-08-13 20:05 EST
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
IDYAIDEAYA Biosciences2026-07-17 13:00 EST
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
KYMRKymera2026-09-01 11:00 EST
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
ELVNEnliven Therapeutics2026-08-31 22:05 EST
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
IDYAIDEAYA Biosciences2026-08-31 10:00 EST
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
FATEFate Therapeutics2026-09-16 11:00 EST
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
LEGNLegend Biotech Corporation2026-09-10 12:00 EST
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
FATEFate Therapeutics2026-09-09 11:00 EST
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Caribou
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic...
Recent company news
CRBUCaribou2026-08-13 20:05 EST
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
CRBUCaribou2026-06-11 12:01 EST
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
CRBUCaribou2026-06-11 12:00 EST
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
CRBUCaribou2026-05-27 20:05 EST
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Stock data
- Close
- 1.31 USD
- Market cap
- 230.1M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States